Physician profile
Stuart Geffner
NPI 1649213422
$7,294.24
in general payments reported to CMS, 2019-2025
10 companies · $153 in 2025
The $153 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $45.19 · 2022: $26.97 · 2023: $150 · 2024: $6,743 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,540 · Food and Beverage: $506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,540.00 |
| Food and Beverage | $506.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $6,540.00 | 2024 | Harmonic, Echelon Flex |
| Dilon Technologies, INC. | $223.14 | 2024-2025 | Hemoblast Bellows |
| Medtronic, INC. | $198.52 | 2023-2024 | Signia, Ligasure |
| Ethicon US, LLC | $132.24 | 2019-2025 | Ethicon |
| Csl Behring | $71.48 | 2019-2020 | |
| Integra Lifesciences Corporation | $52.92 | 2024-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Merck Sharp & Dohme LLC | $27.16 | 2019 | |
| Avanos Medical | $18.89 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.00 | 2020 | |
| Abbvie INC. | $14.89 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Geffner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.